Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis

Jakob M Riedl,Florian Posch,Lena Horvath,Antonia Gantschnigg,Felix Renneberg,Esther Schwarzenbacher,Florian Moik,Dominik A Barth,Christopher H Rossmann,Michael Stotz,Renate Schaberl-Moser,Martin Pichler,Herbert Stöger,Richard Greil,Angela Djanani,Konstantin Schlick,Armin Gerger

European Journal of Cancer（2021）

引用 31|浏览22

暂无评分

摘要

•Propensity score–adjusted comparative effectiveness analysis.•Real-world palliative first-line treatment in advanced pancreatic cancer.•FOLFIRINOX and gemcitabine/nab-paclitaxel have similar effectiveness.•Findings are consistent across all relevant patient's subgroups.

查看译文

关键词

Pancreatic cancer,FOLFIRINOX,Gemcitabine/nab-paclitaxel,First-line treatment,Real-world,Propensity score

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要